Abstract:siRNA therapy offers immense potential for clinical application. Under physiological conditions, however, siRNA was demonstrated to have a short half-life. Additionally, it may also cause ubiquitous gene silencing as it does not possess a tissue-specific homing mechanism. Thus, the rate-limiting step in the emergence of siRNA as a potential therapeutic agent is the current lack of a safe and tissue- or cell-specific in vivo delivery system. Herein, we propose a novel, cell-specific method for the in vivo delivery of siRNA to dendritic cells (DCs) with the purpose of inducing immune modulation. CD40 siRNA was incorporated within the interior of 86 nm liposomes, which were decorated with surface-bound mAb NLDC-145 as a targeting mechanism. The siRNA encapsulation efficiency was determined to be approximately 7%. CD40 siRNA immunoliposomes (CD40 siILs) were able to specifically bind to DCs and silence CD40 expression in vitro. Furthermore, in vitro CD40-silenced DCs significantly inhibited the proliferation of alloreactive T cells in an MLR. Upon in vivo administration, siIL-encapsulated, Cy3-labeled siRNA exhibited moderate uptake by the liver at an early time point following administration with greater accumulation in the spleen at a later time point. In contrast, naked siRNA primarily accumulated in the kidney immediately after administration and circulated out in a short time period. To address in vivo gene silencing and immune modulation, mice were simultaneously immunized with KLH and subcutaneously injected with DC-specific CD40 siILs, siILs containing negative control siRNA, naked CD40 siRNA, or PBS. A second injection of CD40 siILs, or control treatments, followed 24 h later. Flow cytometry, reverse transcriptase PCR, and quantitative real-time PCR analysis of CD11c(+) DCs from mice treated with CD40 siILs demonstrated reduced expression of CD40, in comparison with control groups. CD11c(-) cells were also analyzed by flow cytometry, but no differences were observed between treatment groups. Furthermore, CD40 siIL-treated mice were found to have an increased proportion of Treg cells (CD4(+)CD25(+) FoxP3(+)), and DCs cells from these mice were able to inhibit T cell proliferation in an antigen-specific recall response. In summary, CD40 siILs were shown to specifically target and deliver CD40 siRNA to DCs, significantly reducing CD40 expression and resulting in DC-mediated immune modulation as well as generation of Treg cells. These findings highlight the therapeutic potential for siRNA-based and DC-mediated immunotherapy in the clinic. To the best of our knowledge, this is the first study to use siILs for targeted delivery of siRNA to DCs and for immune modulation.

Nanoparticle Delivery of CD40 Sirna Suppresses Alloimmune Responses by Inhibiting Activation and Differentiation of DCs and Macrophages

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Permanent Acceptance of Mouse Cardiac Allografts with CD40 Sirna to Induce Regulatory Myeloid Cells by Use of a Novel Polysaccharide Sirna Delivery System

A Novel Sirna Delivery System Specifically Silencing Target Gene to Induce Permanent Acceptance of Mouse Cardiac Allograft

Synergic silencing of costimulatory molecules prevents cardiac allograft rejection

Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

In Situ Repurposing of Dendritic Cells with CRISPR/Cas9-based Nanomedicine to Induce Transplant Tolerance.

Cell Communication‐Mediated Selective Drug Delivery for Epitope‐Specific Deletion of Alloreactive T Cells in Organ Transplant

Single-Cell Heterogeneity Restorative Chimeric Engineering Nanoparticles for Alleviating Antibody-Mediated Allograft Injury.

Delivery of costimulatory blockade to lymph nodes promotes transplant acceptance in mice

Sirna Specific Delivery System for Targeting Dendritic Cells.

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Targeting peripheral immune organs with self‐assembling prodrug nanoparticles ameliorates allogeneic heart transplant rejection

PD-L1 Cellular Nanovesicles Carrying Rapamycin Inhibit Alloimmune Responses in Transplantation.

Blockade of CD40 pathway enhances the induction of immune tolerance by immature dendritic cells genetically modified to express cytotoxic T lymphocyte antigen 4 immunoglobulin.

Costimulatory Blockade of CD154-CD40 in Combination with T-cell Lymphodepletion Results in Prevention of Allogeneic Sensitization

Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation

Dual‐Targeting Nanovesicles Carrying CSF1/CD47 Identified from Single‐Cell Transcriptomics of Innate Immune Cells in Heart Transplant for Alleviating Acute Rejection

Administration of Dendritic Cells Transduced with Antisense Oligodeoxyribonucleotides Targeting CD80 or CD86 Prolongs Allograft Survival.

Nanomaterials Mediated Co‐Stimulation of toll‐like Receptors and CD40 for Antitumor Immunity